Business Wire
BusinessMorgan Stanley’s Ethereum ETF filing points to staking-based returns, while markets focus on an expected tickerThe Apex TimesBusinessNvidia’s Vera Rubin rollout could slip, but analyst view on the upside remains intactThe Apex TimesBusinessBlackRock CEO Larry Fink points to “market strength” and “momentum” as shares rise after resultsThe Apex TimesBusinessAnalyst downgrade and valuation debate roil Apple shares as Jim Cramer pushes backThe Apex TimesBusinessBlackRock reports its crypto-related assets fell 39% in the second quarterThe Apex TimesBusinessAmazon MGM releases trailer for “I Play Rocky,” a 1976-era origin story set to hit theaters in November 2026The Apex TimesBusinessSpotify expands “managed accounts” for young listeners to more families and more plansThe Apex TimesBusinessRaytheon, an RTX unit, outlines progress on Army’s Next Generation Short Range InterceptorThe Apex TimesBusinessJohnson & Johnson reports Q2 earnings and revenue above estimates, as investors look for durability across segmentsThe Apex TimesBusinessWarren Buffett tells CNBC his Berkshire Alphabet bet was his idea, but he still is not a top-five fanThe Apex TimesBusinessVisa rolls out an AI Financial Assistant aimed at banks and cardholdersThe Apex TimesBusinessAlibaba’s Qwen AI receives China approval to support Apple devices, according to Yahoo FinanceThe Apex TimesBusinessMorgan Stanley’s Ethereum ETF filing points to staking-based returns, while markets focus on an expected tickerThe Apex TimesBusinessNvidia’s Vera Rubin rollout could slip, but analyst view on the upside remains intactThe Apex TimesBusinessBlackRock CEO Larry Fink points to “market strength” and “momentum” as shares rise after resultsThe Apex TimesBusinessAnalyst downgrade and valuation debate roil Apple shares as Jim Cramer pushes backThe Apex TimesBusinessBlackRock reports its crypto-related assets fell 39% in the second quarterThe Apex TimesBusinessAmazon MGM releases trailer for “I Play Rocky,” a 1976-era origin story set to hit theaters in November 2026The Apex TimesBusinessSpotify expands “managed accounts” for young listeners to more families and more plansThe Apex TimesBusinessRaytheon, an RTX unit, outlines progress on Army’s Next Generation Short Range InterceptorThe Apex TimesBusinessJohnson & Johnson reports Q2 earnings and revenue above estimates, as investors look for durability across segmentsThe Apex TimesBusinessWarren Buffett tells CNBC his Berkshire Alphabet bet was his idea, but he still is not a top-five fanThe Apex TimesBusinessVisa rolls out an AI Financial Assistant aimed at banks and cardholdersThe Apex TimesBusinessAlibaba’s Qwen AI receives China approval to support Apple devices, according to Yahoo FinanceThe Apex TimesBusinessMorgan Stanley’s Ethereum ETF filing points to staking-based returns, while markets focus on an expected tickerThe Apex TimesBusinessNvidia’s Vera Rubin rollout could slip, but analyst view on the upside remains intactThe Apex TimesBusinessBlackRock CEO Larry Fink points to “market strength” and “momentum” as shares rise after resultsThe Apex TimesBusinessAnalyst downgrade and valuation debate roil Apple shares as Jim Cramer pushes backThe Apex TimesBusinessBlackRock reports its crypto-related assets fell 39% in the second quarterThe Apex TimesBusinessAmazon MGM releases trailer for “I Play Rocky,” a 1976-era origin story set to hit theaters in November 2026The Apex TimesBusinessSpotify expands “managed accounts” for young listeners to more families and more plansThe Apex TimesBusinessRaytheon, an RTX unit, outlines progress on Army’s Next Generation Short Range InterceptorThe Apex TimesBusinessJohnson & Johnson reports Q2 earnings and revenue above estimates, as investors look for durability across segmentsThe Apex TimesBusinessWarren Buffett tells CNBC his Berkshire Alphabet bet was his idea, but he still is not a top-five fanThe Apex TimesBusinessVisa rolls out an AI Financial Assistant aimed at banks and cardholdersThe Apex TimesBusinessAlibaba’s Qwen AI receives China approval to support Apple devices, according to Yahoo FinanceThe Apex TimesBusinessMorgan Stanley’s Ethereum ETF filing points to staking-based returns, while markets focus on an expected tickerThe Apex TimesBusinessNvidia’s Vera Rubin rollout could slip, but analyst view on the upside remains intactThe Apex TimesBusinessBlackRock CEO Larry Fink points to “market strength” and “momentum” as shares rise after resultsThe Apex TimesBusinessAnalyst downgrade and valuation debate roil Apple shares as Jim Cramer pushes backThe Apex TimesBusinessBlackRock reports its crypto-related assets fell 39% in the second quarterThe Apex TimesBusinessAmazon MGM releases trailer for “I Play Rocky,” a 1976-era origin story set to hit theaters in November 2026The Apex TimesBusinessSpotify expands “managed accounts” for young listeners to more families and more plansThe Apex TimesBusinessRaytheon, an RTX unit, outlines progress on Army’s Next Generation Short Range InterceptorThe Apex TimesBusinessJohnson & Johnson reports Q2 earnings and revenue above estimates, as investors look for durability across segmentsThe Apex TimesBusinessWarren Buffett tells CNBC his Berkshire Alphabet bet was his idea, but he still is not a top-five fanThe Apex TimesBusinessVisa rolls out an AI Financial Assistant aimed at banks and cardholdersThe Apex TimesBusinessAlibaba’s Qwen AI receives China approval to support Apple devices, according to Yahoo FinanceThe Apex Times
Back to front
Johnson & Johnson set to report second-quarter results Tuesday, with Wall Street looking for higher earnings per share
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 15, 8:10 AM EDT

Johnson & Johnson set to report second-quarter results Tuesday, with Wall Street looking for higher earnings per share

Ahead of the opening bell on Wednesday, July 15, analysts are looking for Johnson & Johnson to post quarterly earnings of $2.85 per share, compared with $2.77 per share a year earlier. A Yahoo Finance piece also framed the event as an opportunity for income-seeking investors, though it did not provide details in the information available here.

3 min readEditor-approved Apex article

Johnson & Johnson is scheduled to release its second-quarter earnings report before the opening bell on Wednesday, July 15, according to a market note published by Yahoo Finance. The company’s upcoming results are expected to be closely watched by investors trying to gauge whether the company’s performance is holding up heading into the middle of the year.

In the Yahoo Finance report, analysts are expected to show quarterly earnings per share (EPS) of $2.85. That would represent an increase from $2.77 per share reported in the same quarter a year earlier, suggesting modest year-over-year improvement that could influence near-term sentiment around the stock.

The Yahoo Finance story’s headline leaned into a personal-finance framing, describing a way to “earn $500 a month” from Johnson & Johnson shares ahead of earnings. However, based on the available excerpted information, the specific mechanics of that “$500 a month” approach (for example, whether it relies on dividends, option income, or another strategy) are not detailed here, and those details would need to be verified in the full article.

Because the report is positioned as market news rather than a company filing, it does not itself add new operating disclosures about Johnson & Johnson’s business. Instead, it points to the timing of the earnings event and the consensus EPS expectation, both of which can shape how trading activity evolves in the days leading up to the release.

Johnson & Johnson, a large-cap healthcare company, is widely followed partly because its results often act as a barometer for broader demand trends in pharmaceuticals and medical devices. When consensus expectations shift, even modestly, it can affect how investors price the company’s earnings power heading into the next quarter.

For investors, the pre-earnings window typically serves as a referendum on whether the company can meet or beat expectations, and whether any guidance or commentary changes the outlook. With EPS expectations indicating growth from the prior year, the key question for the market will be whether the company’s actual results and any commentary align with that trajectory.

What is not available in the information provided is any breakdown of revenue, segment performance, guidance, or management commentary. In addition, the Yahoo Finance excerpt does not disclose whether the “income” framing is tied specifically to the dividend, share repurchases, or derivative strategies, so readers should treat the “$500 a month” framing as a claim that depends on the omitted details of the underlying method.

Going into the print, the most actionable items to watch are the reported quarterly EPS versus the $2.85 expectation referenced in the note, and what management says about demand and margins. Any variance from consensus, especially if it comes with updated outlook language, is likely to drive stock movement once the report is released.

Why It Matters

  • Pre-earnings expectations around EPS can strongly influence how investors position ahead of the release.
  • A year-over-year EPS increase, even if modest, can affect perceived earnings momentum across healthcare large caps.
  • Income-oriented market narratives often drive additional trading activity around earnings, but the underlying strategy details are crucial to evaluate.
  • The first reaction in the stock is likely to hinge on whether results track the cited $2.85 consensus number and what management indicates about the next quarter.

Sources

Key Facts

  • Johnson & Johnson is expected to release its second-quarter earnings report before the opening bell on Wednesday, July 15.
  • The Yahoo Finance market note cites an analyst consensus EPS expectation of $2.85 for the quarter.
  • That $2.85 figure is compared with $2.77 EPS from the same quarter a year earlier.
  • The Yahoo Finance headline frames the period before earnings as a way to generate income from the stock, but the specific method is not provided in the excerpted information here.

Healthcare Related

Jul 15, 7:40 AM EDT
The Apex Times

Eli Lilly backs AdvanCell as its funding round tops $315 million

AdvanCell Pty, a biotechnology company supported by Eli Lilly and Co., has secured $315 million in new financing to advance an experimental cancer therapy, highlighting continued investor appetite for early-stage oncology science.

Eli Lilly backs AdvanCell as its funding round tops $315 million
The Apex Times